Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Tokyo VD who wrote (2584)	11/18/1997 9:53:00 AM
From: EyeDrMike	Read Replies (3) \| Respond to of 23519

Is Viagra next?? Zonagen's Trial and Patent Claims are False, According to Asensio & Company PR Newswire, Tuesday, November 18, 1997 at 09:01 NEW YORK, Nov. 18 /PRNewswire/ -- Asensio & Company, Inc. today issued the following: Asensio & Company, Inc. today released a report on Zonagen, Inc. (OTC:ZONA). The report includes an analysis of Zonagen's Vasomax clinical trials and patents. Asensio & Company found Zonagen's Phase III clinical trials to be seriously flawed and that Zonagen had no defendable proprietary position in the male impotence pill market. As a result, Asensio & Company initiated coverage with a Strong Sell recommendation on Zonagen shares. The report found Zonagen shares to be grossly overvalued. Asensio & Company believes that Zonagen's excessive stock price may be caused by management's failure to disclose material negative information while exaggerating Vasomax's sale potential. Asensio & Company believes that investors are buying Zonagen shares believing that the company has developed a new drug or owns some proprietary right for a male impotence treatment pill. This is completely false and untrue. Zonagen does not own a patent for any pill to treat impotence. Zonagen's pill has only one active ingredient, phentolamine, which is a 45-year-old generic drug. Phentolamine has been shown to be ineffective in treating impotence. In fact, Zonagen's own Phase II German trial confirmed that phentolamine is ineffective. But even assuming the pills have limited efficacy, Zonagen has no ability to control the sale of phentolamine. Phentolamine pills are already available for sale. So even if the FDA approves a Zonagen NDA filing it will have little or no impact on the market or Zonagen's value. Zonagen has not proven it has developed an effective impotence treatment. Zonagen has merely conducted tests using phentolamine as a treatment for impotence. Zonagen has not made a complete disclosure of these tests to either the medical or financial community. While Zonagen claims the tests were successful it has failed to file an NDA. On the contrary, instead of filing an NDA Zonagen is conducting a new test that is larger than all its other tests combined. Asensio's report concludes that Zonagen's Phase III tests were fundamentally flawed in design and execution. Despite these flaws, we believe Zonagen's test results clearly show the pills are ineffective. Asensio & Company, Inc. is a New York based investment banking and securities brokerage firm. Asensio & Company's research report on Zonagen is available on the Internet at www.asensio.com SOURCE Asensio & Company, Inc. -0- 11/18/97 /CONTACT: Chehrazad Paulino of Asensio & Company, 212-702-8805/